Fiche publication
Date publication
juillet 2015
Journal
Inflammatory bowel diseases
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Chandar AK, Singh S, Murad MH, Peyrin-Biroulet L, Loftus EV
Lien Pubmed
Résumé
We assessed the risk-benefit profile of anti-α4-integrins, natalizumab (NAT), and vedolizumab (VEDO), in Crohn's disease through a systematic review and meta-analysis of randomized controlled trials.
Mots clés
Antibodies, Monoclonal, Humanized, therapeutic use, Crohn Disease, drug therapy, Gastrointestinal Agents, therapeutic use, Humans, Immunologic Factors, therapeutic use, Natalizumab, therapeutic use, Remission Induction
Référence
Inflamm. Bowel Dis.. 2015 Jul;21(7):1695-708
